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LETTERS TO THE EDITOR
Is it the creatine or the anabolic androgenic steroids? Need for assessing the steroids role in
testicular cancer
Patrick Cazorla-Saravia*,1 and Renee´ Pereyra-Elı´as1
1MD Escuela de medicina, Universidad Peruana de Ciencias Aplicadas, Calle El Paraı´so 170, La Molina, Lima 12, Peru
Sir,
We have read with considerable interest the case-control study by Li et al.
(2015), in which muscle building supplement (MBS) use was found as an
associated factor with testicular germ cell cancer. It is important to remark
that the association remained statistically significant even after controlling for
important potential confounders. However, we consider that there is one non-
assessed variable that might be relevant in the multi-causal model for
testicular cancer.
Previous research shows that the frequency of anabolic androgenic steroid
(AAS) use within practitioners of recreational physical activity can be as high
as 30 (Abrahin et al, 2014) to 50% (Dodge et al, 2011). Therefore, there is high
probability of concomitant AAS and MBS use. In addition, AASs have been
associated with the development of some types of cancer. Nandrolone and
stanozolol, two of the most used AASs, have proven to enhance Leydig cell
proliferation, increasing the risk of tumour development in rats (Chimento
et al, 2012). There is also suggestive evidence that involves AAS in Leydig cell
tumour growth in humans (Belli et al, 2013). In this scenario, AAS could be
playing an undetected role in malignancy development instead of or in
conjunction with MBS.
Moreover, two recently published articles detected the presence of AAS in
products marketed as dietary supplements (Abbate et al, 2014; Odoardi et al,
2015). Thus, the MBS consumed by Li’s study participants could have been
contaminated with AAS. This highly probable mix of substances does not allow
us to convincingly blame one specific compound.
In summary, Li’s results provide valuable information suggestive of MBS
use as a potential risk factor for testicular cancer. However, future research
considering the potential AAS effect should be carried out in order to clarify
the real influence of this substance.
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Comment on ‘Impact of intra-arterial chemotherapy including internal carotid artery for advanced
paranasal sinus cancers involving the skull base’
Paolo Bossi*,1, Ester Orlandi1 and Lisa Licitra1
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Head and Neck Medical Oncology Unit, Via Venezian, 1, Milano, Italy
Sir,
We read with great interest the paper by Yokoyama J et al, 2014. ‘Impact of
intra-arterial chemotherapy including internal carotid artery for advanced
paranasal sinus cancers involving the skull base’.
There are some major issues that in our opinion strongly limit the
possibility of drawing any conclusions.
The paper presents the experience of intra-arterial cisplatin chemotherapy
(46 patients) compared with historical controls (11 patients) not employing
infusion of the internal carotid artery, presenting survival data of both series.
However, it is difficult to make any comparison, as there is no histology
specification about the treated cancers, which can have a significant prognostic
impact in paranasal sinus cancers (Ganly et al, 2005; Llorente et al, 2014).
The inclusion criteria of this study have not been specified. For example, it
is unclear how many patients were considered and how many were eligible;
this would help in understanding the feasibility of this approach. How many
cases were judged as unresectable? This is the group of patients having the
worst prognosis, which indeed would benefit from alternative approaches such
as intra-arterial chemotherapy (Hoppe et al, 2008); on the other hand, when a
paranasal sinus cancer is resectable, surgery represents the standard treatment
followed by radiotherapy (Dulguerov and Allal, 2006).
Moreover, it is very unclear if the adopted therapeutic strategy was the
same for all cases. The authors stated that 29 of 32 patients with invasion of
orbital apex were treated with preservation of the orbital contents, probably
suggesting that radiotherapy was given in a preoperative setting.
Therefore, it is vital to clarify whether radiotherapy was administered with
radical intent or preoperatively. The reported total dose of 60Gy to tumour
and nodal metastasis with standard fractionation could hardly be curative if
definitive treatment was planned. In fact, receiving a total dose of at least
65Gy is known to be a significant prognostic factor for both tumour local
control and overall survival at least in unresectable paranasal sinus cancers
(Hoppe et al, 2008). Furthermore, no specific data on surgery has been
provided in the paper.
In the statistical part, larynx-preservation rates are calculated and
compared between the two groups. In our experience larynx preservation is
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never an issue for skull base tumours. We wonder whether laryngectomies
were done for late unexpected toxicity?
It should be stressed that choosing to employ intra-arterial monoche-
motherapy and not systemic polychemotherapy could have reduced the
positive effect of systemic therapy in preventing disease metastatisation. This
fact should be discussed also in light of the fact that 50% of the recurrences in
the experimental arm was at a distant site.
The paper presents long-term data about outcome, but no data about late
toxicities are reported. Previous studies showed late effects (brain necrosis,
osteonecrosis, hearing or visual problems) as possible limiting toxicities of
intra-arterial chemotherapy (Homma et al, 2009, 2013).
Keeping all these observations in mind, it is hard to agree with the authors’
conclusions, suggesting that this new method of chemotherapy could be safe
and with promising applications for advanced paranasal sinus cancer.
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